Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Dissection of non-genetic resistance mechanisms by lineage tracing and single cell multiomics reveals drug-specific persister programs in Acute Myeloid Leukemia

Karanpreet Bhatia, Xiao Xian Lin, Ankit Jana, Emanuelle Grody, Ryan Jeremy Lim Jing Wei, Shawn Koh Jia Jun, Elisha Teh Jia Yu, Cin thet Kyi, Prasad Iyer, Greg Kellogg, Yogesh Goyal, Lawrence Boise, Yaara Oren, Shruti Bhatt

Blood (2025) 146 (Supplement 1): 640.

https://doi.org/10.1182/blood-2025-640

Published: 2025

Journal Articles

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Anna Baj, Jonathan Patton, Robert Chavez, Shannon Matulis, Doris Powell, Mala Shanmugam, Arun Wiita, Constantine Mitsiades, Jonathan Keats, Jonathan Licht, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 572.

https://doi.org/10.1182/blood-2025-572

Published: 2025

Journal Articles

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Evangelos Papadopoulos, Ricardo De Matos Simoes, Olga Dashevsky, Huihui Tang, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Yuefang Deng, Aktas Bertal, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2025-2581

Published: 2025

Journal Articles

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Ajay Nooka, Nishi Shah, Lawrence Boise, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2025-2823

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Kiran Lakhani, Yu Zhang, Jonathan Keats, Vikas Gupta, Sagar Lonial, Nisha Joseph, Ajay Nooka, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2025-2251

Published: 2025

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

Angelica Amanso, Karanpreet Bhatia, Mackenzie Mekler, James Ackley, Pankoj Das, London Harper, Holly Lee, Madhav Dhodapkar, Stanley Riddell, Paola Neri, Nizar Bahlis, Sagar Lonial, Adam Marcus, Lawrence Boise

Blood (2025) 146 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2025-1031

Published: 2025

Journal Articles

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Robert Chavez, Jonathan Patton, James Ackley, Mala Shanmugam, Constantine Mitsiades, Arun Wiita, Jonathan Licht, Erin Flynt, Terry Connolly, Karen Conneely, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2025-3956

Published: 2025

Journal Articles

Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma

James Ackley, Sagar Lonial, Damian Green, Stanley Riddell, Geoff Hill, Madhav Dhodapkar, Lawrence Boise

Blood (2025) 146 (Supplement 1): 3953.

https://doi.org/10.1182/blood-2025-3953

Published: 2025

Journal Articles

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Beena Thomas, Karanpreet Bhatia, Devin Bog, Benjamin Barwick, Constantine Mitsiades, Lawrence Boise, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2025-5733

Published: 2025

Journal Articles

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Shannon Matulis, Jonathan Patton, Rebecca Owens, Robert Chavez, Arun Wiita, Mala Shanmugam, Constantine Mitsiades, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2025-2177

Published: 2025

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma

Mansour Poorebrahim, David Jung, Holly Lee, Sacha Benaoudia, Sungwoo Ahn, Noemie Leblay, Sejal Chikhale, Elham Hasheminasabgo, Anja Barbour, Lawrence Boise, Paola Neri, Nizar Bahlis

Blood (2025) 146 (Supplement 1): 914.

https://doi.org/10.1182/blood-2025-914

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).

James R. Berenson, MD, Ralph Vincent V. Boccia, M.D., Mohamad A. Hussein, M.D., Andrew Belch, M.D., Lawrence Boise, M.D., Brian Schwartz, M.D., Robert Peter Gale, M.D.,Ph.D., Steven M. Kornblau, M.D.

Blood (2006) 108 (11): 1966.

https://doi.org/10.1182/blood.V108.11.1966.1966

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Dissection of non-genetic resistance mechanisms by lineage tracing and single cell multiomics reveals drug-specific persister programs in Acute Myeloid Leukemia

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only